Clinical Trial

IntroductionLynch syndrome (LS) is a hereditary cancer syndrome that increases risk for colorectal and other cancers. We hypothesize that vaccines against tumor-associated antigens CEA, MUC1, and brachyury, simultaneously delivered in an adenovirus ser…

BackgroundRecessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis caused by biallelic COL7A1 mutations, where chronic inflammation drives disabling complications affecting quality of life and survival. Effective inflammatory c…

BackgroundMost patients with hepatocellular carcinoma (HCC) are diagnosed at intermediate or advanced stages, when curative resection is not feasible. Conversion therapy aiming to downstage tumors and enable surgical resection has emerged as a potentia…

BackgroundMucosal melanomas arise from melanocytes in mucosal tissues, and it’s usually detected at a late stage owing to its anatomic location. Advances in immunotherapies have proved to be promising therapeutic approaches for advanced mucosal melanom…

IntroductionB001 is a recombinant humanized anti-CD20 monoclonal antibody targeting CD20+ B cells, that has demonstrated superior B cell depletion and anti-proliferative and cytotoxic effects compared to rituximab in a pre-clinical study. The present p…

BackgroundThe one-strength injection regimen has increasingly become the mainstream paradigm for subcutaneous immunotherapy (SCIT). This study aimed to assess the safety and tolerability of an optimal accelerated scheme for SCIT using a house dust mite…

BackgroundDuring the COVID-19 pandemic, adenoviral vector-based Sputnik V vaccine was used to vaccinate the civilian population of 74 countries worldwide. As part of laboratory monitoring of the effectiveness of the Sputnik V vaccine, a decrease in eff…

IntroductionCOVID-19 boosters restore waning immunity. After demonstrating non-inferiority of 15 μg versus 30 μg BNT162b2 at 28 days in Mongolian adults, we assessed 24-month immunogenicity and safety.MethodsIn this randomised, controlled trial, adults…

PurposeThe purpose of this study was to prospectively evaluate the clinical efficacy and safety of baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, in the treatment of patients with Vogt–Koyanagi–Harada (VKH) disease.DesignThe study was des…

IntroductionCancer-related pain remains a critical clinical challenge, with existing opioid-based therapies often yielding inadequate relief and significant side effects. This study investigates the therapeutic potential of JK5G postbiotics—a formulati…